ETF Holdings Breakdown of ARCT

ARCT institutional holdings

The following institutional investment holdings of ARCT have been identified

Date	ETF ISIN/Name	Num Shares	Book value	Derived Price per Share	Comment
2025-11-27	IE00BYZK4776 (iShares Healthcare Innovation UCITS ETF USD (Acc))	26,453	USD 179,880	6.80
2025-11-27	IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc))	19,111	USD 129,955	6.80
2025-11-27	IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist))	19,111	USD 129,955	6.80
Total =		64,675	USD 439,790

Book value of shares is calculated on the adjusted close price of each day (row).

News associated with ARCT

Arcturus Therapeutics (NASDAQ:ARCT) Given New $54.00 Price Target at Leerink Partners

Arcturus Therapeutics (NASDAQ:ARCT – Free Report) had its price target cut by Leerink Partners from $63.00 to $54.00 in a report released on Friday,Benzinga reports. They currently have an outperform rating on the biotechnology company’s stock. ARCT has been the subject of a number of other reports. Canaccord Genuity Group decreased their target price on […] - 2025-08-25 02:12:53

Mitsubishi UFJ Asset Management Co. Ltd. Grows Position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)

Mitsubishi UFJ Asset Management Co. Ltd. increased its position in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT – Free Report) by 9.2% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 14,693 shares of the biotechnology company’s stock after buying an additional 1,232 shares during […] - 2025-08-15 04:46:53

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives Average Rating of “Buy” from Brokerages

Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT – Get Free Report) have received an average rating of “Buy” from the seven analysts that are currently covering the firm, MarketBeat.com reports. Seven analysts have rated the stock with a buy recommendation. The average 1 year target price among analysts that have issued ratings on the stock […] - 2025-08-12 04:42:57

Empire Life Investments Inc. Sells 14,554 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)

Empire Life Investments Inc. trimmed its position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT – Free Report) by 5.2% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 264,909 shares of the biotechnology company’s stock after selling 14,554 shares during the period. […] - 2025-08-04 04:44:57

Alps Advisors Inc. Trims Stock Holdings in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)

Alps Advisors Inc. reduced its holdings in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT – Free Report) by 8.9% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 19,949 shares of the biotechnology company’s stock after selling 1,952 shares during the quarter. Alps Advisors Inc. owned approximately […] - 2025-07-18 04:49:09

Sumitomo Mitsui Trust Group Inc. Reduces Stock Position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)

Sumitomo Mitsui Trust Group Inc. reduced its position in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT – Free Report) by 6.7% in the first quarter, HoldingsChannel.com reports. The firm owned 1,926,084 shares of the biotechnology company’s stock after selling 138,966 shares during the period. Sumitomo Mitsui Trust Group Inc. owned about 0.07% of Arcturus Therapeutics […] - 2025-07-04 05:12:59

Arcturus Therapeutics (NASDAQ:ARCT) Stock Crosses Below 200 Day Moving Average – Time to Sell?

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT – Get Free Report)’s share price crossed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $14.13 and traded as low as $13.74. Arcturus Therapeutics shares last traded at $14.41, with a volume of 517,333 shares changing hands. Wall Street Analyst […] - 2025-06-27 05:22:55

Arcturus Therapeutics (NASDAQ:ARCT) Now Covered by Scotiabank

Scotiabank began coverage on shares of Arcturus Therapeutics (NASDAQ:ARCT – Get Free Report) in a report released on Wednesday, Marketbeat Ratings reports. The brokerage set a “sector outperform” rating and a $32.00 price target on the biotechnology company’s stock. Scotiabank’s price objective would suggest a potential upside of 151.37% from the company’s previous close. A […] - 2025-05-30 02:38:46

Cresset Asset Management LLC Sells 2,198 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)

Cresset Asset Management LLC decreased its position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT – Free Report) by 16.0% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 11,511 shares of the biotechnology company’s stock after selling 2,198 shares during the period. Cresset Asset Management LLC’s holdings in […] - 2025-05-19 05:02:55

Arcturus Therapeutics (NASDAQ:ARCT) Given New $66.00 Price Target at Canaccord Genuity Group

Arcturus Therapeutics (NASDAQ:ARCT – Free Report) had its target price reduced by Canaccord Genuity Group from $68.00 to $66.00 in a research note issued to investors on Tuesday morning,Benzinga reports. They currently have a buy rating on the biotechnology company’s stock. ARCT has been the topic of a number of other research reports. HC Wainwright […] - 2025-05-14 04:58:54

Hsbc Holdings PLC Increases Stake in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)

Hsbc Holdings PLC grew its position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT – Free Report) by 11.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 25,368 shares of the biotechnology company’s stock after acquiring an additional 2,673 shares during the […] - 2025-05-08 06:07:00

Barclays PLC Lowers Position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)

Barclays PLC trimmed its position in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT – Free Report) by 10.9% in the 4th quarter, Holdings Channel.com reports. The firm owned 60,082 shares of the biotechnology company’s stock after selling 7,333 shares during the period. Barclays PLC’s holdings in Arcturus Therapeutics were worth $1,020,000 as of its most […] - 2025-05-06 04:38:59

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Stock Holdings Lessened by Franklin Resources Inc.

Franklin Resources Inc. lessened its holdings in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT – Free Report) by 3.1% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 100,677 shares of the biotechnology company’s stock after selling 3,259 shares during the period. […] - 2025-04-15 05:32:54

Mitsubishi UFJ Asset Management Co. Ltd. Purchases 4,647 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)

Mitsubishi UFJ Asset Management Co. Ltd. lifted its position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT – Free Report) by 52.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 13,461 shares of the biotechnology company’s stock after acquiring an additional 4,647 […] - 2025-04-04 05:12:56

AlphaQuest LLC Sells 12,668 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)

AlphaQuest LLC cut its stake in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT – Free Report) by 63.9% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 7,142 shares of the biotechnology company’s stock after selling 12,668 shares during the period. AlphaQuest LLC’s holdings in […] - 2025-03-19 06:06:45

Arcturus Therapeutics (NASDAQ:ARCT) Given New $68.00 Price Target at Canaccord Genuity Group

Arcturus Therapeutics (NASDAQ:ARCT – Get Free Report) had its price objective reduced by stock analysts at Canaccord Genuity Group from $74.00 to $68.00 in a research report issued on Monday,Benzinga reports. The firm presently has a “buy” rating on the biotechnology company’s stock. Canaccord Genuity Group’s price objective would indicate a potential upside of 414.76% […] - 2025-03-12 04:08:56

Arcturus Therapeutics (NASDAQ:ARCT) Share Price Passes Below 200-Day Moving Average – Here’s Why

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT – Get Free Report) passed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $18.81 and traded as low as $16.51. Arcturus Therapeutics shares last traded at $16.69, with a volume of 364,852 shares. Wall Street Analysts Forecast Growth Several research […] - 2025-02-25 06:50:59

Spire Wealth Management Increases Stock Holdings in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)

Spire Wealth Management increased its holdings in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT – Free Report) by 393.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 13,478 shares of the biotechnology company’s stock after buying an additional 10,746 shares during the […] - 2025-02-07 07:05:06

Back to Listing

Disclaimer